Yes, intranasal fluticasone can be used for sinusitis and provides modest but clinically meaningful symptom relief, particularly for acute post-viral rhinosinusitis.
Intranasal fluticasone is effective for treating acute rhinosinusitis, reducing total symptom scores and accelerating time to clinical improvement, though the effect size is modest (number needed to treat of 11-14). 1, 2
Evidence Quality and Recommendations
The most recent and comprehensive guideline evidence comes from the European Position Paper on Rhinosinusitis 2020 (EPOS2020), which provides the strongest framework for decision-making 1:
For Acute Post-Viral Rhinosinusitis (Adults)
- Fluticasone propionate nasal spray (FPNS) significantly shortens time to clinical success when added to antibiotics in patients with recurrent or chronic rhinitis history 1, 3
- The Dolor 2001 study demonstrated FPNS (2 puffs twice daily for 21 days) increased treatment success from 74% to 93% and improved work performance 1
- Symptom improvement occurs as early as 12 hours, with maximum benefit achieved within several days 4
Dosing Algorithm
For adults with acute rhinosinusitis:
- Start with 200 mcg once daily (two 50-mcg sprays per nostril) for 15-21 days 1, 4
- Alternative: 100 mcg twice daily (one spray per nostril twice daily)
- For patients ≥12 years with seasonal allergic rhinitis component: as-needed use of 200 mcg once daily may be effective 4
For children 4-11 years:
- Start with 100 mcg once daily (one spray per nostril) 4
- Reserve 200 mcg daily only for inadequate responders
- Maximum dose: 200 mcg/day
Important Clinical Context
When to Prescribe
The EPOS2020 guideline advises prescribing intranasal corticosteroids only when symptom reduction is considered necessary, given that acute post-viral rhinosinusitis is self-limiting 1. The American Academy of Otolaryngology guideline (2015, updated 2025) similarly positions intranasal steroids as an option for symptomatic relief alongside analgesics and saline irrigation 2, 5.
Patient Selection Nuances
Best candidates for fluticasone:
- Patients with recurrent acute rhinosinusitis or chronic rhinitis history show greater benefit 1, 3
- Patients with nasal congestion as predominant symptom (intranasal steroids specifically improve congestion) 1
- Patients seeking to avoid or delay antibiotics
Limited benefit in:
- Sporadic, non-recurrent acute rhinosinusitis without underlying chronic inflammation 2
- Patients with symptoms <10 days (likely viral rhinosinusitis) 2
Combination Therapy Considerations
The 2005 guideline notes that intranasal corticosteroids as adjunct to antibiotic therapy may be helpful in recurrent acute and chronic sinusitis 6. However, the 2015 guideline cautions that benefits may not apply to sporadic ABRS as strictly defined 2.
Safety Profile
Minor adverse events only:
No difference in therapy-related local adverse events compared to placebo in major trials 1
Pediatric Growth Monitoring
For children on prolonged therapy, monitor growth velocity routinely (e.g., stadiometry), as intranasal corticosteroids may reduce growth velocity even without HPA axis suppression 4. However, a 1-year study in children ages 3-9 showed no statistically significant growth effect with fluticasone 200 mcg daily 4.
Chronic Rhinosinusitis Context
While your question focuses on sinusitis broadly, note that fluticasone via exhalation delivery system (EDS-FLU) shows superior efficacy for chronic rhinosinusitis with nasal polyps compared to standard nasal sprays, with significant improvements in SNOT-22 scores and polyp reduction 7, 8, 9, 10. This represents an important advancement for refractory cases.
Cost-Effectiveness
EPOS2020 cites cost-effectiveness modeling showing mometasone furoate (similar intranasal steroid) was cost-saving compared to amoxicillin or placebo for post-viral rhinosinusitis 1. This supports intranasal steroids as economically rational despite modest effect size.
Key Pitfall to Avoid
Do not prescribe fluticasone as monotherapy expecting cure of bacterial sinusitis. Its role is symptomatic relief and reducing inflammation. The 2015 guideline emphasizes that none of these products are FDA-approved specifically for acute rhinosinusitis 2, though clinical evidence supports their use.